Home › Free Stock Grades › LCTX
Lineage Cell Therapeutics, Inc. (LCTX) Stock Grade
LCTX · Healthcare
C
Market Cap
$242.1M
P/E Ratio
—
Revenue Growth (YoY)
+53.2%
Net Margin
-436.5%
Return on Equity
—
Dividend Yield
None
About Lineage Cell Therapeutics, Inc.'s fundamentals
Lineage Cell Therapeutics is a biotechnology company with a market capitalization of $242.1 million that reported strong revenue growth of 53.2% year-over-year, indicating expanding commercial activity or funding. However, the company is currently unprofitable with a net margin of -436.5%, reflecting substantial operating losses relative to its revenue base. The company does not pay dividends and reported a net loss in its latest annual statement, which is typical for early-stage biotechnology firms investing heavily in research and development.